LOGIN
Substantial anti-resorptive effects achieved with 1mg and 2.5mg doses of zoledronate
July 2013
Substantial anti-resorptive effects achieved with 1mg and 2.5mg doses of zoledronate
Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:N/A
Low-dose zoledronate in osteopenic postmenopausal women: a randomized controlled trial
J Clin Endocrinol Metab. 2012 Jan;97(1):286-92. doi: 10.1210/jc.2011-2081. Epub 2011 Nov 9Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
One hundred and eighty postmenopausal women with osteopenia were randomized into 4 groups and received either a single IV infusion of 5mg, 2.5mg, 1mg, or placebo zoledronate to determine the antiresorptive properties of each dose. Bone mineral density and bone turnover were assessed 12 months after administration. The results indicated that the lower doses produced considerable antiresorptive effe...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
The OE High Impact metric uses AI to determine the impact a study will have by considering the content of the article itself. Built using the latest advances of natural language processing techniques. OE High Impact predicts an article’s future number of citations than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.